2021 ACR/VF指南：巨细胞动脉炎和大动脉炎的管理

2021-07-08 美国风湿病学会 Arthritis Rheumatol.2021 Jul 8.

2021年7月，美国风湿病学会(ACR)联合血管炎基金会(VF)共同发布了巨细胞动脉炎和大动脉炎的管理指南。巨细胞动脉炎（GCA）和大动脉炎（TAK）是主要影响大中型血管的系统性血管炎，本文主要针对G

中文标题：

英文标题：

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis

发布机构：

美国风湿病学会

发布日期：

2021-07-08

简要介绍：

2021年7月，美国风湿病学会(ACR)联合血管炎基金会(VF)共同发布了巨细胞动脉炎和大动脉炎的管理指南。巨细胞动脉炎（GCA）和大动脉炎（TAK）是主要影响大中型血管的系统性血管炎，本文主要针对GCA和TAK的管理提供循证建议和专家指导。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=a45561c002133571, title=2021 ACR/VF指南：巨细胞动脉炎和大动脉炎的管理, enTitle=2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis, guiderFrom=Arthritis Rheumatol.2021 Jul 8., authorId=0, author=, summary=2021年7月，美国风湿病学会(ACR)联合血管炎基金会(VF)共同发布了巨细胞动脉炎和大动脉炎的管理指南。巨细胞动脉炎（GCA）和大动脉炎（TAK）是主要影响大中型血管的系统性血管炎，本文主要针对G, cover=https://img.medsci.cn/2021722/1626958713493_2020535.jpg, journalId=0, articlesId=null, associationId=528, associationName=美国风湿病学会, associationIntro=The American College of Rheumatology's mission is advancing rheumatology. The organization is for physicians, health professionals, and scientists that meets the mission through programs of education, research, advocacy and practice support. The ACR provides professional education for its members through several venues. The Annual Scientific Meeting, held each fall, is the premier scientific meeting devoted to the rheumatic diseases. This meeting draws thousands of rheumatologists and arthritis health professionals from around the world. A winter rheumatology symposium, spring clinical meetings, and other topical conferences round out the ACR's educational offerings., copyright=0, guiderPublishedTime=Thu Jul 08 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年7月，美国风湿病学会(ACR)联合血管炎基金会(VF)共同发布了巨细胞动脉炎和大动脉炎的管理指南。巨细胞动脉炎（GCA）和大动脉炎（TAK）是主要影响大中型血管的系统性血管炎，本文主要针对GCA和TAK的管理提供循证建议和专家指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=383, tagName=大动脉炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=383, guiderKeyword=大动脉炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8715, appHits=191, showAppHits=0, pcHits=1668, showPcHits=8523, likes=2, shares=18, comments=12, approvalStatus=1, publishedTime=Thu Jul 22 22:12:09 CST 2021, publishedTimeString=2021-07-08, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 22 20:58:43 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 20:12:44 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ACR_VF指南：巨细胞动脉炎和大动脉炎的管理.pdf)])

2021 ACR_VF指南：巨细胞动脉炎和大动脉炎的管理.pdf

下载请点击：

评论区 (11)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2180838, encodeId=f206218083890, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b7e2626091, createdName=tingtingff, createdTime=Thu Jan 11 20:26:40 CST 2024, time=2024-01-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2121678, encodeId=842221216e81c, content=有中文好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e51531845, createdName=kjdoctor, createdTime=Fri Mar 24 22:34:01 CST 2023, time=2023-03-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1213164, encodeId=fbc1121316477, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:06 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212658, encodeId=26b91212658a0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:42:43 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067517, encodeId=4dfd106e5178a, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=993b5605874, createdName=ms3000000026674545, createdTime=Sat Nov 06 10:56:52 CST 2021, time=2021-11-06, status=1, ipAttribution=)]
2024-01-11 tingtingff 来自山东省

感谢分享

59 0
[GetPortalCommentsPageByObjectIdResponse(id=2180838, encodeId=f206218083890, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b7e2626091, createdName=tingtingff, createdTime=Thu Jan 11 20:26:40 CST 2024, time=2024-01-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2121678, encodeId=842221216e81c, content=有中文好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e51531845, createdName=kjdoctor, createdTime=Fri Mar 24 22:34:01 CST 2023, time=2023-03-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1213164, encodeId=fbc1121316477, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:06 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212658, encodeId=26b91212658a0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:42:43 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067517, encodeId=4dfd106e5178a, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=993b5605874, createdName=ms3000000026674545, createdTime=Sat Nov 06 10:56:52 CST 2021, time=2021-11-06, status=1, ipAttribution=)]
2023-03-24 kjdoctor 来自河南省

有中文好

91 0
[GetPortalCommentsPageByObjectIdResponse(id=2180838, encodeId=f206218083890, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b7e2626091, createdName=tingtingff, createdTime=Thu Jan 11 20:26:40 CST 2024, time=2024-01-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2121678, encodeId=842221216e81c, content=有中文好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e51531845, createdName=kjdoctor, createdTime=Fri Mar 24 22:34:01 CST 2023, time=2023-03-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1213164, encodeId=fbc1121316477, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:06 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212658, encodeId=26b91212658a0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:42:43 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067517, encodeId=4dfd106e5178a, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=993b5605874, createdName=ms3000000026674545, createdTime=Sat Nov 06 10:56:52 CST 2021, time=2021-11-06, status=1, ipAttribution=)]
2022-04-21 135434d0m28暂无昵称

谢谢分享

109 0
[GetPortalCommentsPageByObjectIdResponse(id=2180838, encodeId=f206218083890, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b7e2626091, createdName=tingtingff, createdTime=Thu Jan 11 20:26:40 CST 2024, time=2024-01-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2121678, encodeId=842221216e81c, content=有中文好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e51531845, createdName=kjdoctor, createdTime=Fri Mar 24 22:34:01 CST 2023, time=2023-03-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1213164, encodeId=fbc1121316477, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:06 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212658, encodeId=26b91212658a0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:42:43 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067517, encodeId=4dfd106e5178a, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=993b5605874, createdName=ms3000000026674545, createdTime=Sat Nov 06 10:56:52 CST 2021, time=2021-11-06, status=1, ipAttribution=)]
2022-04-19 qqnded

感谢分享

111 0
[GetPortalCommentsPageByObjectIdResponse(id=2180838, encodeId=f206218083890, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b7e2626091, createdName=tingtingff, createdTime=Thu Jan 11 20:26:40 CST 2024, time=2024-01-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2121678, encodeId=842221216e81c, content=有中文好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e51531845, createdName=kjdoctor, createdTime=Fri Mar 24 22:34:01 CST 2023, time=2023-03-24, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1213164, encodeId=fbc1121316477, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:06 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212658, encodeId=26b91212658a0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:42:43 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067517, encodeId=4dfd106e5178a, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=993b5605874, createdName=ms3000000026674545, createdTime=Sat Nov 06 10:56:52 CST 2021, time=2021-11-06, status=1, ipAttribution=)]
2021-11-06 ms3000000026674545

很好

123 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

风湿免疫科指南

2021 ACR/VF指南：巨细胞动脉炎和大动脉炎的管理

拓展阅读

科室

工具

服务